About Us
Hepobio Provides an Integrated Service Portfolio for Drug Toxicity Prediction, Disease Model Development and Mechanistic Research
Hepabio is dedicated to the development and application of advanced 3D microtissue platforms, delivering robust safety, efficacy, and metabolic evaluations to support preclinical drug development. Our founding team originates from the Karolinska Institute, home to the Nobel Assembly for the Nobel Prize in Physiology or Medicine. We have partnered with more than sixty leading pharmaceutical companies worldwide, providing industry-trusted preclinical evaluation solutions that accelerate innovative drug development.
0
％
Specificity
0
％
Sensitivity
0
+
Partners
Products & Services
To Build Internationally Advanced 3D Micro-tissue Platforms
Safety Assessment
To systematically assess the potential toxicity risks of drugs or compounds in organisms, our company offers a series of specialized safety evaluation testing products.
Evaluation of Compound Efficacy
To build a professional efficacy evaluation platform covering major disease areas and new therapies, focusing on fields such as metabolism and immunity.
In Vitro ADME
Provide systematic studies on drug absorption, distribution, metabolism and excretion.
Mechanism Research
Focusing on drug action mechanisms, providing in-depth analysis from the molecular, cellular to pathway levels.

Policy Guidance

Follow the Policy Guidance Closely and Focus on Development
2011
The Ministry of Science and Technology of the People's Republic of China launched new drug project "Key Technologies for New Drug Research and Development Based on Microfluidic Chips".
2019
The Ministry of Science and Technology of the People's Republic of China released the "Guidelines for Applications for Key Projects in the 14th Five-Year Plan for National Key R&D Program in 2021", emphasizing the construction of stem cell-based models for major intractable human diseases.
2022
The Center for Drug Evaluation (CDE) has officially recommended the use of organ-on-a-chip technologies for preclinical safety and efficacy evaluation in its guidelines for cell and gene therapies as well as stem cell therapies.
2025
The US government announced the start of project on “human on chip”.
2013
The project "Precision Mesoscopic Measurement of Human Organs-on-Chips" was approved as part of the first batch of key R&D initiatives for transformative technologies under the National Key Scientific Issues Program by the Ministry of Science and Technology of the People's Republic of China.
2021
The Food and Drug Administration (FDA) amended the law to include in vitro models as an independent preclinical evaluation system.
2024
FDA announced plan to phase out animal testing of monoclonal antibodies and other drugs. In April 2025, the FDA clearly proposed for the first time that within 3-5 years, animal experiments would become an auxiliary evaluation method, new methods such as organoids would become the mainstream evaluation method, and the reform of ICH regulations would be promoted.